摘要
目的:探索信迪利单抗联合呋喹替尼治疗微卫星稳定型(MSS)晚期结肠癌的临床疗效及对患者免疫功能的影响。方法:选取于2018年12月至2020年12月于江苏大学附属武进医院就诊的76例晚期结肠癌患者作为研究对象,随机分为对照组和观察组,每组38例。对照组给予呋喹替尼治疗,观察组给予信迪利单抗联合呋喹替尼治疗。对比两组患者治疗6个月的临床疗效,并分别于治疗前后采集外周血,采用流式细胞实验测定T淋巴细胞亚群(CD3^(+)T、CD4^(+)T、CD8^(+)T、CD4^(+)T/CD8^(+)T)变化,采用ELISA实验测定补体(C3、C4)和免疫球蛋白(IgA、IgG、IgE)水平。出院后完成2~3年随访,绘制生存曲线,比较生存与无进展生存情况。结果:治疗6个月,观察组疾病控制率(86.84%)优于对照组(60.53%);客观缓解率(36.84%)优于对照组(13.16%),差异有统计学意义(P<0.05)。治疗前,两组T淋巴细胞亚群、补体和免疫球蛋白水平差异不大;治疗后6个月,观察组CD4^(+)T/CD8^(+)T、IgA及IgG水平高于对照组,差异有统计学意义(P<0.05)。观察组治疗1年与2年的生存率优于对照组,治疗2年的无进展生存率优于对照组,截至随访结束时中位生存期和无进展生存期均高于对照组,差异有统计学意义(P<0.05)。两组患者各不良反应发生率差异均无统计学意义(P>0.05)。结论:信迪利单抗联合呋喹替尼治疗MSS晚期结肠癌的临床疗效优于呋喹替尼单药,对患者免疫功能的影响相对较小,不良反应可耐受,具有潜在应用价值。
Objective:To explore the clinical efficacy of Sintilimab combined with Fruquintinib in the treatment of microsatellite stability(MSS)advanced colon cancer and its effect on the immune function of patients.Methods:A total of 76 patients with advanced colon cancer treated in Wujin Hospital Affiliated to Jiangsu University from December 2018 to December 2020 were selected as the study objects and randomly divided into control group and observation group,with 38 cases in each group.Patients in the control group was treated with Fruquintinib,and in the observation group was treated with Sintilimab combined with Fruquintinib.The clinical efficacy after 6 months of treatment was compared between the two groups.Peripheral blood was collected before and after treatment,and the changes of T lymphocyte subsets(CD3+T,CD4+T,CD8+T,CD4+T/CD8+T)were determined by flow cytometry.The complement(C3,C4)and immunoglobulin(IgA,IgG,IgE)levels were determined by ELISA assay.A 2 to 3 years follow-up was completed after discharge,and survival curves were drawn to compare survival and progression-free survival.Results:After 6 months of treatment,the disease control rate of the observation group was 86.84%,which was better than 60.53%in control group.The objective remission rate was 36.84%,which was better than 13.16%in control group,and the difference between the two groups was statistically significant(P<0.05).Before treatment,there were no significant differences in T lymphocyte subsets,complement and immunoglobulin levels between the two groups,while 6 months after treatment,the levels of CD4+T/CD8+T,IgA and IgG in the observation group were higher than those in control group,and the differences were statistically significant(P<0.05).The 1-year and 2-year survival rate of observation group was better than control group,and the 2-year progression-free survival rate was better than that of control group(P<0.05).By the end of follow-up,the median survival and progression-free survival were longer than that of the control group,with statist
作者
朱麒
刘迁
肖敏
肖瑶
潘儒艳
金丽艳
王月
ZHU Qi;LIU Qian;XIAO Min;XIAO Yao;PAN Ruyan;JIN Liyan;WANG Yue(Wujin Hospital Affiliated to Jiangsu University,Wujin Clinical College of Xuzhou Medical University,Changzhou 213003,China)
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2023年第9期1922-1927,共6页
Chinese Journal of Immunology
基金
国家自然科学基金资助项目(81872275)
江苏省高校重点实验室开放课题(XZSYSKF2020005)
常州市武进区科学科技局项目(WS201924)。
关键词
信迪利单抗
呋喹替尼
微卫星稳定型晚期结肠癌
免疫功能
Sintilimab
Fruquintinib
Microsatellite stability advanced colorectal cancer
Immune function
